cell lines Cds1 and Cds2, as well as in benign and malignant prostate tumor tissues (10). A 1 recent review points out that there is extensive disagreement between the published profiles of 2 microRNAs in prostate cancer (11). The differences could arise from limitations of the 3 hybridization method for detecting the small RNAs and from the wide variability of malignant 4 tissue content in clinical samples.
5
All published expression profiles of miRNAs in prostate cancer depended on microarray 6 hybridization and none utilized the recently available profiling method of next generation 7 sequencing of miRNAs. In this paper, we systematically examined the expression profile of 8 miRNAs in an androgen-dependent human prostate cancer cell line LNCaP and its derivative 9 castration-resistant more advanced cell line C4-2 using both Roche 454 sequencing and 10 miRCURY LNA microarray platform. We confirmed the changes that were concordant by the 11 two methods by miRNA-specific quantitative RT-PCR to identify four miRNAs, miR-125b and 12 members of miR-99 family (miR-99a, -99b, -100), that were down-regulated in C4-2 relative to 13 LNCaP. These miRNAs were decreased in human prostate tumor tissue compared to normal miRNA microarray profiling was carried out using Exiqon miRCURY LNA array system (v.9.2).
9
Cloning of small RNAs and Roche 454 deep sequencing 10 Small RNA cloning was performed as described in Lau's paper with minor modifications (13) .
11
Small RNA with a size of 17-26 nt was gel purified from 500 µg of total RNA. Purified small
12
RNA was ligated with a modified 3'-adaptor, followed by a 5'-adaptor ligation, PCR 
16
Luciferase reporter assay 17 The 3'-UTR fragments of SMARCD1, SMARCA5, mTOR and PPFIA3 containing miR-99 1 was performed as described (14). The total RNAs from monoribosome and polyribosome 2 fractionations were extracted separately, and subjected to qRT-PCR analysis for individual 3 mRNAs.
4
BrdU Incorporation and PSA ELISA assay 5 BrdU incorporation was measured as previously described (15) and was normalized to cell 6 density measured by MTT assay (Promega). PSA ELISA assay was performed using culture 7 supernatant 72 hr after siRNA/miRNA duplex transfection using Human PSA ELISA Kit 8 (Abazyme) according to the manufacturer's instructions and normalized to MTT assay. 
Results

12
Screening for differential expression of miRNAs in prostate cancer cells: 13 Small RNAs of 17-26 nucleotides were cloned from two prostate cancer cell lines, LNCaP 14 and C4-2, and subjected to 454 deep sequencing. A flowchart for the analysis of 454 deep 15 sequencing data is outlined in Fig S1 . The sequencing reads, ~190,000 from each sample, were 16 compared with one another to yield unique sequences and their cloning frequencies. In further 17 analysis, we only included unique sequences cloned five times or more, which add up to more 18 than a thousand. Among them, a few hundred sequences were cloned more than 50 times (Table   19   S1 ). small RNAs in the cloned sequences; 37% of sequencing reads were mapped to miRNAs in the 1 database (Table S1) . A report on the analysis of the non-miRNA short RNAs has been published 2 (17). Altogether, 293 miRNAs were cloned from the two cell lines. The most frequently cloned 3 miRNAs were let-7 family members, miR-125b, -99a, -200c, -17, and -21, suggesting that these 4 miRNAs are abundant in these cell lines (Table S2) .
5
Significant change in the relative cloning frequency of several miRNAs between LNCaP 6 and C4-2 (Table 1) suggested that these miRNAs are differentially expressed between the two 7 cell lines. To confirm the changes in these miRNAs, we obtained miRNA expression profile 8 from LNA (Locked Nucleic Acid)-microarray and compared the array data to the 454 9 sequencing data. Based on these two data sets, the expression of several miRNAs was measured 10 by quantitative PCR (Fig 1A) . The data are summarized in Table 1 . In general, the qRT-PCR 11 results are more consistent with the microarray data than 454 sequencing data, probably because 12 both qRT-PCR and microarray are hybridization-based methods.
13
miR-100, -125b, -19b, and miR-99a were the most down-regulated miRNAs in C4-2 14 relative to LNCaP. miR-20a, -106a, -99b, -21 and miR-16 were modestly decreased in C4-2. In 15 contrast, miR-9, -557 and -196b were the most up-regulated in C4-2 relative to LNCaP (with 16 more than two fold changes confirmed by at least two methods). The differential expression of 17 these miRNAs between LNCaP and the more advanced C4-2 lead us to hypothesize that the 18 change of these miRNAs may be important in the progression of prostate cancer. cancer cell line WPE1-NB26 derived from RWPE-1. miR-125b and members of miR-99 family 1 (miR-99a, miR-99b, and miR-100) also exhibited a significant decrease in WPE1-NB26 2 compared to RWPE1 cells (Fig 1B) .
3
To evaluate if the differential expression of miRNAs in the cell lines was also seen in 4 human tumor specimens, we performed miRNA qRT-PCR from 10 human prostate tumor 5 samples and 10 normal prostate tissue samples. miR-125b and miR-99 family were significantly 6 decreased in the human prostate tumor samples compared to normal tissue (Fig 1C) androgen R1881 (Fig 1D, E) . This inhibition of androgen-independent growth by the miR-99 18 family requires the presence of AR, as the miR-99 family does not affect the growth of PC3 and
19
Du145 cells (Fig S2) . Thus, the reduction of miR-99 family, seen during the progression from miR-99a, miR-99b and miR-100 belong to the same family with a shared seed sequence 1 (nucleotides 2-7 of the miRNA), which is known to be the critical determinant in recognition of 2 target mRNAs (Fig S3A) . Therefore, miR-99 family members are predicted to target a common regulated by at least a third by miR-99a (Table 2) . add this assay to our filters.
We tested 8 out of 19 genes in Table 2 by the ribosome fractionation assay before and 20 after miR-99a transfection. These genes were selected based on previous literature implicating 21 their involvement in prostate cancer. Upon the transfection of miR-99a, all eight genes were 22 accumulated in the monosome fraction (Table 2) . Among these genes, SMARCA5, SMARCD1, 23 PPFIA3, and FRAP1/mTOR exhibited more than 5 fold accumulations in the monoribosome 1 fraction. For comparison, their mRNA levels were reduced by about 2 fold after introduction of 2 miR-99a (Table 2) . Consistent with the decreased loading of ribosomes onto these mRNAs, the 3 protein levels of all four genes were all decreased by one or more members of the miR-99 family 4 (Fig 2A and B) . Thus, these four genes are likely to be direct targets of miR-99 family and were 5 further tested in the following experiments.
6
Confirming targets as directly repressed by miR-99 family in luciferase reporter assay: 7 Targetscan predicted one recognition site of miR-99 family in the 3'-UTR region of 8 SMARCD1, SMARCA5, mTOR and PPFIA3 ( Fig S4A) . We inserted the 3'UTR fragments 9 downstream of luciferase ORF in a reporter plasmid in order to test whether they are directly 10 repressed by the miR-99 family. For FRAP1/mTOR, SMARCA5, and SMARCD1, the 3'-UTRs 11 conferred repression of the heterologous luciferase ORF after transfection of miR-99a, miR-99b 12 or miR-100 (Fig 2C-E) . In all three cases, the repression by miR-99 family was abolished when 13 we mutated the predicted target sites (Fig S4B, Fig 2C-E) . In case of PPFIA, we did not observe 14 any significant reduction of luciferase expression by miR-99 family (Fig 2F) . Thus, the reduction 15 of PPFIA3 mRNA and protein by miR-99 family (Table 2 and Fig 2A and B) was either due to 16 an indirect effect or due to a target site in the open reading frame. cells, in a dose dependent manner ( Fig 3A) . As a positive control for androgen activity, we 1 checked that R1881 stimulated the level of PSA mRNA, an androgen-responsive gene ( Fig S6A) . antisense oligonucleotides against them (Fig 3B) . To test whether the change in the secreted PSA 16 level was due to the impaired AR activity, we tested the mRNA expression of two AR regulated 17 genes PSA and SARG. We observed a similar decrease in mRNA level of both PSA and SARG 18 after transfection of miR-99 family miRNAs (Fig 3C and Fig S6B) . The protein level of PSA 19 also showed a decrease after overexpression of miR-99/100 (Fig 3D) . We next tested whether expression (Fig 3B-D) . Knockdown of mTOR by siRNA decreases both the PSA mRNA and 1 protein level (Fig 3B-D) . Thus, repression of these targets could contribute to PSA repression by 2 the miR-99 family, though the chromatin remodeling factors SMARCD1 and SMARCA5 appear (Fig S6C-D) . Our results suggest that loss of miR-99 family affects AR-driven gene 13 expression, particularly the expression of PSA at both mRNA and protein level (Fig 4B) . The de- Identifying bona fide miRNA targets has been a difficult step in studying miRNAs. Bartel group reported that genes whose proteins were repressed more than 50% by miRNAs also 18 exhibit mRNA degradation (32) . Therefore, mRNA microarray is widely used to determine the 19 actual targets of the miRNA. In many cases, however, the modest change in mRNA level is not polyribosome fractionation screen, we were able to increase the true positive rate of candidate 10 genes to >75%. A large scale screening of candidate genes by subjecting the RNAs from 11 polyribosome and monoribosome fractions to sequencing or microarray would be very useful to 12 identify target genes of miRNAs in a future study. (Fig S6C, D) . Thus, at least one other unknown target of miR-99/100 must be important for 17 decreasing AR activity at the PSA promoter. repressed by hepatocyte-specific miRNA miR-122 (43) . In this paper, we showed that the miR-11 99 family also represses the expression of SMARCD1 at both mRNA and protein level.
12
SMARCD1 is required for PSA protein expression but is not sufficient by itself to restore PSA previously reported in clear cell ovarian cancer model (47). In this study, we showed that mTOR 1 is repressed not only by miR-100, but also its family members miR-99a and miR-99b. mTOR is 2 required for expression of PSA mRNA (Fig 3B) , but not for maintaining AR levels (Fig S5A) . It 3 will be interesting to elucidate how mTOR impact on AR activity at the PSA promoter.
4
In summary, we implicated that the miRNAs of miR-99 family are repressed and three 5 validated targets are de-repressed during the genesis and progression of prostate cancer. We also 6 showed that miR-99 family represses AR activity and independently repress PSA protein level 7 through SMARCA5 (Fig 4B) . The consistent decrease of miR-99 family in the human prostate 8 tumors increases the possibility of using them as a signature of prostate cancer progression. Our 9 study also underlines the possible treatment of prostate cancer by restoring the level of miR-99 10 family members. Finally, in pursuing the targets of these tumor suppressive miRNAs, we make 11 the exciting discovery that the SMARCA5 chromatin remodeling factor is important for post-12 transcriptional regulation of a metastatic factor, PSA. 
